表紙
市場調查報告書
商品編碼
966724

尿細管性酸中毒:市場分析,流行病學,市場預測 (2030年)

Renal Tubular Acidosis - Market Insight, Epidemiology and Market Forecast - 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 115 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球主要7個國家──美國,歐洲主要5國 (EU5:法國·德國·義大利·西班牙·英國 ),日本──的尿細管性酸中毒的疫情趨勢和今後的市場預測相關分析,彙整疾病概要和市場基本結構,目前治療方法與未滿足需求,患病人數趨勢預測,已上市/臨床實驗中的治療藥的簡介,全球整體/各國的市場規模 (過去3年·今後11年份),主要的推動及阻礙市場要素等資訊,為您概述為以下內容。

目錄

第1章 主要考察

第2章 尿細管性酸中毒:摘要整理

第3章 尿細管性酸中毒的競爭資訊分析

第4章 尿細管性酸中毒:市場概要

  • 整體市場佔有率結構 (2017年)
  • 整體市場佔有率結構 (2030年)

第5章 尿細管性酸中毒:疾病概要

  • 簡介
  • 徵兆與症狀
  • 病理生理學
  • 危險因素
  • 診斷標準

第6章 患者治療流程

第7章 尿細管性酸中毒的流行病學和患者人口

  • 流行病學分析的要點
  • 假設和理論的根據:主要7個國家
  • 流行病學方案:主要7個國家
    • 尿細管性酸中毒:主要7個國家的流行病學方案 (2017年∼2030年)
  • 美國的疫情趨勢
    • 美國國內的尿細管性酸中毒的流行病學方案 (2017年∼2030年)
  • 歐洲5個國家:各國疫情趨勢
    • 德國的疫情趨勢
    • 法國的疫情趨勢
    • 義大利的疫情趨勢
    • 西班牙的疫情趨勢
    • 英國的疫情趨勢
  • 日本的疫情趨勢

第8章 治療流程,目前治療·診療方法

  • 尿細管性酸中毒的治療·管理方法
  • 尿細管性酸中毒的治療流程

第9章 未滿足需求

第10章 尿細管性酸中毒治療藥的主要端點

第11章 已上市產品

  • 主要7個國家所販售產品一覽
  • 藥名:企業名
    • 產品說明
    • 法規的里程碑
    • 其他開發活動
    • 重要的臨床實驗:概要

第12章 新治療藥

  • 主要產品一覽
  • 藥名:企業名
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第13章 尿細管性酸中毒:主要7個國家的市場分析

  • 分析主要的要點
  • 尿細管性酸中毒的市場規模:主要7個國家
  • 尿細管性酸中毒的市場規模:主要7個國家,各治療藥物

第14章 屬性分析

第15章 主要7個國家:市場未來展望

  • 美國的市場規模
    • 尿細管性酸中毒的整體市場規模
    • 市場規模:各治療藥物
  • 歐洲主要5個國家 (EU5) 市場:市場規模與未來展望
    • 德國的市場規模
    • 法國的市場規模
    • 義大利的市場規模
    • 西班牙的市場規模
    • 英國的市場規模
  • 日本市場:市場規模與未來展望

第16章 尿細管性酸中毒的就醫與醫療費給付:概要

第17章 產業的有學識者 (KOL)的見解

第18章 推動市場要素

第19章 市場阻礙因素

第20章 附錄

第21章 DelveInsight的服務內容

第22章 免責聲明

第23章 關於DelveInsight

目錄
Product Code: DIMI1127

DelveInsight's 'Renal Tubular Acidosis Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Renal Tubular Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Renal Tubular Acidosis market report provides analysis regarding current treatment practices, emerging drug-like ADV7103 (Advicenne), potential therapies, market share of the individual therapies, historical, current, and forecasted Renal Tubular Acidosis market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Renal Tubular Acidosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Renal Tubular Acidosis - Disease Understanding and Treatment Algorithm

Renal Tubular Acidosis Overview

Renal tubular acidosis (RTA) is a disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person's blood to remain too acidic. The term renal tubular acidosis (RTA) is applied to a group of transport defects in the reabsorption of bicarbonate (HCO3-), the excretion of hydrogen ion (H+), or both. This condition was first described in 1935, confirmed as a renal tubular disorder in 1946, and designated "renal tubular acidosis" in 1951.

RTA defines a class of disorders in which excretion of hydrogen ions or reabsorption of filtered bicarbonate is impaired, leading to a chronic metabolic acidosis with a normal anion gap. Symptoms may vary for different types of distal renal tubular acidosis; some commonly shown symptoms are as follows: confusion or decreased alertness, fatigue, impaired growth in children, increased breathing rate, kidney stones, Nephrocalcinosis (too much calcium deposited in the kidneys), Osteomalacia (softening of the bones) and muscle weakness.

Renal Tubular Acidosis Treatment

This chapter covers the details of conventional and current medical therapies available in the Renal Tubular Acidosis market for the treatment of the condition. It also provides the country-wise Renal Tubular Acidosis treatment guidelines across the United States, Europe, and Japan.

DelveInsight's Renal Tubular Acidosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Renal Tubular Acidosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Renal Tubular Acidosis Epidemiology

The Renal Tubular Acidosis epidemiology chapters provide insights about historical and current Renal Tubular Acidosis patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Renal Tubular Acidosis epidemiology is segmented by Total prevalent cases of Renal Tubular Acidosis, Cases of Renal Tubular Acidosis by gender, Cases of Renal Tubular Acidosis by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific Renal Tubular Acidosis cases. The report includes a thorough analysis of all segmentations.

In the US, the cases of Renal Tubular Acidosis were 45,601 in 2017. Moreover, the Type-specific cases of Renal Tubular Acidosis were highest among Type 1 (distal RTA) and were reported to be 20,064 in the country.

According to DelveInsight's analysis, the total prevalent population of Renal Tubular Acidosis in seven major markets was 1,08,679 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of Renal Tubular Acidosis cases.

Renal Tubular Acidosis Drug Chapters

The drug chapter segment of the Renal Tubular Acidosis report encloses the detailed analysis of Renal Tubular Acidosis pipeline drug. It also helps understand the Renal Tubular Acidosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

The aim is not only to correct the biochemical abnormalities but to fundamentally improve growth in children and to prevent the progression of nephrocalcinosis and the development of chronic renal failure at all ages. The basis of therapy is the continuous administration of appropriate amounts of alkali in the form of either bicarbonate or citrate. The amount of alkali administered should compensate for the urinary loss of HCO3- plus the amount of acid generated by the catabolism of proteins and the skeletal growth. There is just a single therapy in the pipeline for treating individuals with RTA.

Renal Tubular Acidosis Market Outlook

The Renal Tubular Acidosis market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounts for the largest Renal Tubular Acidosis market size, with USD 6.2 million in 2017, while Spain had the smallest market size of Renal Tubular Acidosis with USD 0.9 million in 2017.

Renal Tubular Acidosis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs in the Renal Tubular Acidosis market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Renal Tubular Acidosis market uptake by drugs, patient uptake by therapies, and sale of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of Renal Tubular Acidosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.

Renal Tubular Acidosis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Renal Tubular Acidosis key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of Renal Tubular Acidosis collaborations, acquisition and merger, licensing, patent details, and other information for Renal Tubular Acidosis emerging therapies.

Reimbursement Scenario in Renal Tubular Acidosis

Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Renal Tubular Acidosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Renal Tubular Acidosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, the Renal Tubular Acidosis market scenario is expected to alter across the 7MM due to the launch of a better therapy covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Renal Tubular Acidosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Renal Tubular Acidosis Pipeline Analysis
  • Renal Tubular Acidosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Renal Tubular Acidosis Report Key Strengths

  • 11 years Forecast
  • 7MM Coverage
  • Renal Tubular Acidosis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Renal Tubular Acidosis Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Renal Tubular Acidosis market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the Renal Tubular Acidosis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest Renal Tubular Acidosis market size during the forecast period (2017-2030)?
  • At what CAGR, the Renal Tubular Acidosis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Renal Tubular Acidosis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Renal Tubular Acidosis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of Renal Tubular Acidosis?
  • What is the historical Renal Tubular Acidosis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Renal Tubular Acidosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Renal Tubular Acidosis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Renal Tubular Acidosis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the Renal Tubular Acidosis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Renal Tubular Acidosis in the USA, Europe, and Japan?
  • What is the Renal Tubular Acidosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Renal Tubular Acidosis?
  • How many therapies are developed by each company for Renal Tubular Acidosis treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for Renal Tubular Acidosis treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Renal Tubular Acidosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Renal Tubular Acidosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Renal Tubular Acidosis?
  • What are the global historical and forecasted market of Renal Tubular Acidosis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Renal Tubular Acidosis market
  • To understand the future market competition in the Renal Tubular Acidosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Renal Tubular Acidosis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Renal Tubular Acidosis market
  • To understand the future market competition in the Renal Tubular Acidosis market
  • Which geography accounted for the largest Renal Tubular Acidosis market size?
  • The United States accounted for the largest Renal Tubular Acidosis market size.
  • What is forecasted Renal Tubular Acidosis market size in 2030?
  • DelveInsight estimates an increase in Renal Tubular Acidosis Market Size during the study period, 2017-2030
  • What is the present Renal Tubular Acidosis market drivers?
  • Increasing opportunities and organizational support.
  • What is the Renal Tubular Acidosis market barriers?
  • Drawbacks in the standard of care and focus on single disease outcomes are likely to block the market growth.
  • How many companies are developing drugs for Renal Tubular Acidosis?
  • Currently, there is only one key pharma player engaged in developing the drug for Renal Tubular Acidosis.
  • Which are the leading companies in the Renal Tubular Acidosis market?
  • Key Player- Advicenne
  • How is epidemiology segmented for Renal Tubular Acidosis?

Prevalent Cases of Renal Tubular Acidosis, Renal Tubular Acidosis cases by Gender, Cases of RTA by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific cases of RTA.

Table of Contents

1 Key Insights

2 Executive Summary of Renal Tubular Acidosis

3 SWOT Analysis for Renal Tubular Acidosis

4 Renal Tubular Acidosis Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Renal Tubular Acidosis in 2017
  • 4.2 Market Share (%) Distribution of Renal Tubular Acidosis in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Types of Renal Tubular Acidosis
  • 5.3 Sign and Symptoms
  • 5.4 Clinical Manifestations
  • 5.5 Causes
  • 5.6 Pathophysiology
  • 5.7 Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 7MM Total Prevalent Patient Population of Renal Tubular Acidosis

7 Country Wise-Epidemiology of Renal Tubular Acidosis

    • 7.1.1 Assumptions and Rationale - 7MM
  • 7.2 The United States
    • 7.2.1 Total Prevalent Cases of Renal Tubular Acidosis in the United States
    • 7.2.2 Type-specific Cases of Renal Tubular Acidosis in the United States
    • 7.2.3 Age-specific Cases of Renal Tubular Acidosis in the United States
    • 7.2.4 Cases of Distal Renal Tubular Acidosis by Types in the United States
    • 7.2.5 Gender-specific Cases of Renal tubular Acidosis in the United States
  • 7.3 EU5
  • 7.4 Germany
    • 7.4.1 Total Prevalent Cases of Renal Tubular Acidosis in Germany
    • 7.4.2 Type-specific Cases of Renal Tubular Acidosis in Germany
    • 7.4.3 Age-specific Cases of Renal Tubular Acidosis in Germany
    • 7.4.4 Cases of Distal Renal Tubular Acidosis by Types in Germany
    • 7.4.5 Gender-specific Cases of Renal tubular Acidosis in Germany
  • 7.5 France
    • 7.5.1 Total Prevalent Cases of Renal Tubular Acidosis in France
    • 7.5.2 Type-specific Cases of Renal Tubular Acidosis in France
    • 7.5.3 Age-specific Cases of Renal Tubular Acidosis in France
    • 7.5.4 Cases of Distal Renal Tubular Acidosis by Types in France
    • 7.5.5 Gender-specific Cases of Renal tubular Acidosis in France
  • 7.6 Italy
    • 7.6.1 Total Prevalent Cases of Renal Tubular Acidosis in Italy
    • 7.6.2 Type-specific Cases of Renal Tubular Acidosis in Italy
    • 7.6.3 Age-specific Cases of Renal Tubular Acidosis in Italy
    • 7.6.4 Cases of Distal Renal Tubular Acidosis by Types in Italy
    • 7.6.5 Gender-specific Cases of Renal tubular Acidosis in Italy
  • 7.7 Spain
    • 7.7.1 Total Prevalent Cases of Renal Tubular Acidosis in Spain
    • 7.7.2 Type-specific Cases of Renal Tubular Acidosis in Spain
    • 7.7.3 Age-specific Cases of Renal Tubular Acidosis in Spain
    • 7.7.4 Cases of Distal Renal Tubular Acidosis by Types in Spain
    • 7.7.5 Gender-specific Cases of Renal tubular Acidosis in Spain
  • 7.8 The United Kingdom
    • 7.8.1 Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom
    • 7.8.2 Type-specific Cases of Renal Tubular Acidosis in the United Kingdom
    • 7.8.3 Age-specific Cases of Renal Tubular Acidosis in the UK
    • 7.8.4 Cases of Distal Renal Tubular Acidosis by Types in the UK
    • 7.8.5 Gender-specific Cases of Renal tubular Acidosis in the United Kingdom
  • 7.9 Japan
    • 7.9.1 Total Prevalent Cases of Renal Tubular Acidosis in Japan
    • 7.9.2 Type-specific Cases of Renal Tubular Acidosis in Japan
    • 7.9.3 Age-specific Cases of Renal Tubular Acidosis in Japan
    • 7.9.4 Cases of Distal Renal Tubular Acidosis by Types in Japan
    • 7.9.5 Gender-specific Cases of Renal tubular Acidosis in Japan

8 Treatment

9 Unmet Needs

10 Organizations contributing toward Renal Tubular Acidosis

11 Case Reports

  • 11.1 Renal Tubular Acidosis: As case Discussion in Japan
  • 11.2 Renal Tubular Acidosis: As case discussion in the US

12 Emerging Therapies

  • 12.1 ADV7103: Advicenne
    • 12.1.1 Product Description
    • 12.1.2 Other Development Activities
    • 12.1.3 Clinical Development
    • 12.1.4 Safety and Efficacy

13 Renal Tubular Acidosis: 7 Major Market Analysis

  • 13.1 Key Findings
  • 13.2 Market Size of Renal Tubular Acidosis in 7MM

14 Market Outlook

  • 14.1 7MM Market Outlook
    • 14.1.1 United States Market Size
  • 14.2 EU-5 Countries: Market Outlook
    • 14.2.1 Germany
    • 14.2.2 France
    • 14.2.3 Italy
    • 14.2.4 Spain
    • 14.2.5 United Kingdom
  • 14.3 Japan: Market Outlook
    • 14.3.1 Total Market Size of Renal Tubular Acidosis
    • 14.3.2 Market Size of Renal Tubular Acidosis by Therapies

15 Market Drivers

16 Market Barriers

17 Appendix

  • 17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

  • Table 1: Summary of Renal Tubular Acidosis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Overview of Renal Tubular Acidosis
  • Table 3: Common causes of Renal Tubular Acidosis (RTA)
  • Table 4: Main genetic defects of distal renal tubular acidosis (dRTA) and their associated clinical manifestations
  • Table 5: Diagnostic tests to differentiate distal renal tubular acidosis from other types of renal tubular acidosis
  • Table 6: Prevalent Patient Population of Renal Tubular Acidosis in 7MM (2017-2030)
  • Table 7: Total Prevalent Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Table 8: Type-specific Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Table 9: Age-specific Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Table 10: Cases of Distal Renal Tubular Acidosis by Types in the United States (2017-2030)
  • Table 11: Gender-specific Cases of Renal tubular Acidosis in the United States (2017-2030)
  • Table 12: Total Prevalent Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Table 13: Type-specific Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Table 14: Age-specific Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Table 15: Cases of Distal Renal Tubular Acidosis by Types in Germany (2017-2030)
  • Table 16: Gender-specific Cases of Renal tubular Acidosis in Germany (2017-2030)
  • Table 17: Total Prevalent Cases of Renal Tubular Acidosis in France (2017-2030)
  • Table 18: Type-specific Cases of Renal Tubular Acidosis in France (2017-2030)
  • Table 19: Age-specific Cases of Renal Tubular Acidosis in France (2017-2030)
  • Table 20: Cases of Distal Renal Tubular Acidosis by Types in France (2017-2030)
  • Table 21: Gender-specific Cases of Renal tubular Acidosis in France (2017-2030)
  • Table 22: Total Prevalent Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Table 23: Type-specific Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Table 24: Age-specific Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Table 25: Cases of Distal Renal Tubular Acidosis by Types in Italy (2017-2030)
  • Table 26: Gender-specific Cases of Renal tubular Acidosis in Italy (2017-2030)
  • Table 27: Total Prevalent Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Table 28: Type-specific Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Table 29: Age-specific Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Table 30: Cases of Distal Renal Tubular Acidosis by Types in Spain (2017-2030)
  • Table 31: Gender-specific Cases of Renal tubular Acidosis in Spain (2017-2030)
  • Table 32: Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom (2017-2030)
  • Table 33: Type-specific Cases of Renal Tubular Acidosis in the United Kingdom (2017-2030)
  • Table 34: Age-specific Cases of Renal Tubular Acidosis in the UK (2017-2030)
  • Table 35: Cases of Distal Renal Tubular Acidosis by Types in the UK (2017-2030)
  • Table 36: Gender-specific Cases of Renal tubular Acidosis in the United Kingdom (2017-2030)
  • Table 37: Total Prevalent Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Table 38: Type-specific Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Table 39: Age-specific Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Table 40: Cases of Distal Renal Tubular Acidosis by Types in Japan (2017-2030)
  • Table 41: Gender-specific Cases of Renal tubular Acidosis in Japan (2017-2030)
  • Table 42: Organizations contributing toward Renal Tubular Acidosis
  • Table 43: ADV7103, Clinical Trial Description, 2020
  • Table 44: Seven Major Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 45: United States Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 46: The US Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 47: Germany Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 48: Germany Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 49: France Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 50: France Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 51: Italy Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 52: Italy Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 53: Spain Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 54: Spain Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 55: United Kingdom Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 56: The UK Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Table 57: Japan Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Table 58: Japan Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Proximal Tubule Reabsorption of Bicarbonate
  • Figure 3: Acid Secretion in Collecting Duct
  • Figure 4: Algorithm to differentiate between normal anion gap metabolic acidosis owing to RTA
  • Figure 5: Algorithm for the clinical evaluation of non-anion gap metabolic acidosis
  • Figure 6: Diagnostic Approach to incomplete Distal RTA
  • Figure 7: Prevalent Patient Population of Renal Tubular Acidosis in 7MM (2017-2030)
  • Figure 8: Total Prevalent Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Figure 9: Type-specific Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Figure 10: Age-specific Cases of Renal Tubular Acidosis in the United States (2017-2030)
  • Figure 11: Cases of Distal Renal Tubular Acidosis by Types in the United States (2017-2030)
  • Figure 12: Gender-specific Cases of Renal tubular Acidosis in the United States (2017-2030)
  • Figure 13: Total Prevalent Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Figure 14: Type-specific Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Figure 15: Age-specific Cases of Renal Tubular Acidosis in Germany (2017-2030)
  • Figure 16: Cases of Distal Renal Tubular Acidosis by Types in Germany (2017-2030)
  • Figure 17: Gender-specific Cases of Renal tubular Acidosis in Germany (2017-2030)
  • Figure 18: Total Prevalent Cases of Renal Tubular Acidosis in France (2017-2030)
  • Figure 19: Type-specific Cases of Renal Tubular Acidosis in France (2017-2030)
  • Figure 20: Age-specific Cases of Renal Tubular Acidosis in France (2017-2030)
  • Figure 21: Cases of Distal Renal Tubular Acidosis by Types in France (2017-2030)
  • Figure 22: Gender-specific Cases of Renal tubular Acidosis in France (2017-2030)
  • Figure 23: Total Prevalent Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Figure 24: Type-specific Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Figure 25: Age-specific Cases of Renal Tubular Acidosis in Italy (2017-2030)
  • Figure 26: Cases of Distal Renal Tubular Acidosis by Types in Italy (2017-2030)
  • Figure 27: Gender-specific Cases of Renal tubular Acidosis in Italy (2017-2030)
  • Figure 28: Total Prevalent Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Figure 29: Type-specific Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Figure 30: Age-specific Cases of Renal Tubular Acidosis in Spain (2017-2030)
  • Figure 31: Cases of Distal Renal Tubular Acidosis by Types in Spain (2017-2030)
  • Figure 32: Gender-specific Cases of Renal tubular Acidosis in Spain (2017-2030)
  • Figure 33: Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom (2017-2030)
  • Figure 34: Type-specific Cases of Renal Tubular Acidosis in the United Kingdom (2017-2030)
  • Figure 35: Age-specific Cases of Renal Tubular Acidosis in the UK (2017-2030)
  • Figure 36: Cases of Distal Renal Tubular Acidosis by Types in the UK (2017-2030)
  • Figure 37: Gender-specific Cases of Renal tubular Acidosis in the United Kingdom (2017-2030)
  • Figure 38: Total Prevalent Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Figure 39: Type-specific Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Figure 40: Age-specific Cases of Renal Tubular Acidosis in Japan (2017-2030)
  • Figure 41: Cases of Distal Renal Tubular Acidosis by Types in Japan (2017-2030)
  • Figure 42: Gender-specific Cases of Renal tubular Acidosis in Japan (2017-2030)
  • Figure 43: Unmet Needs of Renal Tubular Acidosis
  • Figure 44: Seven Major Market Size of Renal Tubular Acidosis in USD Million (2017-2030)
  • Figure 45: Market Size of Renal Tubular Acidosis in the United States, USD Million (2017-2030)
  • Figure 46: The US Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 47: Market Size of Renal Tubular Acidosis in Germany, USD Million (2017-2030)
  • Figure 48: Germany Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 49: Market Size of Renal Tubular Acidosis in France USD Million (2017-2030)
  • Figure 50: France Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 51: Market Size of Renal Tubular Acidosis in Italy, USD Million (2017-2030)
  • Figure 52: Italy Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 53: Market Size of Renal Tubular Acidosis in Spain, USD Million (2017-2030)
  • Figure 54: Spain Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 55: Market Size of Renal Tubular Acidosis in the United Kingdom, USD Million (2017-2030)
  • Figure 56: The UK Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 57: Market Size of Renal Tubular Acidosis in Japan, USD Million (2017-2030)
  • Figure 58: Japan Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017-2030)
  • Figure 59: Market Drivers
  • Figure 60: Market Barriers